循环CTRP9与系统性硬化症相关间质性肺病严重程度相关
该回顾性纵向研究纳入110例系统性硬化症(SSc)患者,检测基线血清CTRP9水平并随访肺功能至48个月。结果显示高CTRP9与基线及48个月时更低的用力肺活量占预计值百分比(FVC%)相关,而低CTRP9能较准确识别肺病稳定患者,提示CTRP9可能是SSc相关间质性肺病(ILD)的潜在生物标志物。
要点
- 高循环CTRP9与SSc患者基线及48个月时更低的FVC%相关。
- 低CTRP9识别肺病稳定患者的敏感性为73%。
- CTRP9与肺功能下降轨迹无关,但与小气道功能水平相关。
核心结论
- 高循环CTRP9与更差的肺功能相关,低CTRP9可识别肺病稳定患者,提示CTRP9可能是SSc相关ILD的潜在生物标志物。
研究设计与样本
- 利用西北硬皮病项目患者登记和生物样本库开展的回顾性纵向研究,纳入110例SSc患者,基线检测血清CTRP9,每12个月收集临床和肺功能数据至48个月。
主要发现
- 横断面分析中,高CTRP9组基线FVC%显著低于低CTRP9组(72%±17 vs 80%±18,P=0.02)。
- 48个月时高CTRP9组FVC%仍显著低于低CTRP9组(68±19 vs 84±18,P=0.001)。
- 混合模型分析中,高CTRP9与更差肺功能相关,但与肺功能变化轨迹无关(P=0.23)。
- 低CTRP9识别肺病稳定患者的敏感性为73%。
- 潜在轨迹分析证实低CTRP9与更高FVC%相关。
临床怎么用
- CTRP9可能作为评估SSc相关ILD严重程度和疾病稳定性的生物标志物,高CTRP9提示肺功能更差,低CTRP9提示肺病稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: While interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc), there remains a paucity of predictive markers to assess disease progression. We previously demonstrated that adipose tissue metabolism and adipokine homeostasis is dysregulated in SSc. The present study was undertaken to determine the association and predictive ability of the novel adipokine C1q/tumor necrosis factor-related protein 9 (CTRP9) for SSc-associated ILD. METHODS: We performed a retrospective longitudinal study utilizing the Northwestern Scleroderma Program Patient Registry and Biorepository. Serum levels of CTRP9 were measured in 110 SSc patients at baseline, and demographic, clinical, and pulmonary function test data were collected in 12-month intervals to 48 months. Longitudinal trajectory of forced vital capacity percent predicted (FVC%) was used as a primary outcome measure. We utilized a mixed model to compare trajectories of lung function by CTRP9 groups and performed latent trajectory analysis to accommodate for heterogeneity. RESULTS: In cross-sectional analysis, elevated circulating CTRP9 was associated with significantly lower FVC% at baseline (72% ± 17 versus 80% ± 18; P = 0.02) and 48 months (68 ± 19 versus 84 ± 18; P = 0.001). In mixed model analysis, high CTRP9 was associated with worse lung function but not with a different trajectory (P = 0.23). In contrast, low CTRP9 identified patients with stability of lung disease with reasonable accuracy (sensitivity 73%). Latent trajectory analysis confirmed the association of lower CTRP9 with higher FVC%. CONCLUSION: Higher circulating CTRP9 associated with worse pulmonary function, while low CTRP9 identified patients with lung disease stability over time. These findings suggest that CTRP9 may be a potential biomarker in SSc-associated ILD.
引用
- Yang MM, Balmert LC, Marangoni RG, et al. Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Care Res (Hoboken). 2022. PMID: 34251759. doi:10.1002/acr.24749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。